Prostate cancer: diagnosis and management

Supporting evidence

• Surveillance report

• 2023 exceptional surveillance of prostate cancer: diagnosis and management (NICE guideline NG131)

• Appendix A: Equality and health inequalities assessment (PDF 215 KB)

  Published:

  02 March 2023

• 2021 exceptional surveillance of prostate cancer: diagnosis and management (NICE guideline NG131)

• Evidence review

• Evidence review - 2021

• I: Risk stratification of localised prostate cancer (PDF 1.07 MB)

  Published:

  15 December 2021

• Evidence reviews – May 2019

• A: Bisphosphonates (PDF 1.56 MB)

  Published:

  09 May 2019

• B: Docetaxel in people with hormone-sensitive prostate cancer (PDF 971 KB)

  Published:

  09 May 2019

• C: Radical radiotherapy (PDF 1.44 MB)

  Published:

  09 May 2019

• D: Diagnosing and identifying clinically significant prostate cancer (PDF 2.77 MB)

  Published:

  09 May 2019

• E: Following up people at increased risk of prostate cancer (PDF 4.15 MB)

  Published:

  09 May 2019

• F: Identifying prostate cancer clinical progression in people with low- to intermediate-risk cancer (PDF 1.25 MB)

  Published:

  09 May 2019

• G: Active surveillance, radical prostatectomy or radical radiotherapy in people with localised prostate cancer (PDF 4.88 MB)

  Published:

  09 May 2019

• H: Follow-up protocols after radical treatment (PDF 1.03 MB)

  Published:

  09 May 2019

• Economic analysis

• Health economic model report (PDF 10.35 MB)

  Published:

  20 May 2019

• Full guidance

• Full guideline – January 2014

• Full guideline (PDF 4.86 MB)

  Published:

  08 January 2014